Subscribe to RSS - budesonide


ASP: Budesonide reverses course


BALTIMORE – When it comes to nebulizer medication pricing, one quarter you’re up; another quarter you’re down.

ASP: Winners, losers, audits


BALTIMORE – With few exceptions, the average sales price (ASP) figures for nebulizer medications don’t change much from quarter to quarter. That doesn’t mean the market is stagnant, says Wayne Vega, senior vice president of the Inhalation Drug Group.

In brief: CMS delays F2F rule again, Golden endorses Reverie


BALTIMORE – CMS had no choice but to delay—for the second time—enforcement of its face-to-face rule until sometime in 2014, say industry stakeholders. “We just haven’t seen any further education,*” said Kim Brummett, senior director of regulatory affairs for AAHomecare.

ASP: Budesonide gets big boost


BALTIMORE – Things are looking up for several respiratory medications in the latest average sales price (ASP) figures. For the fourth quarter 2013, budesonide (J7626) took the biggest leap, up 85 cents to $5.95 per dose.

Prices, audits stay the course


BALTIMORE – Brand-name Brovana took a hit in the latest average sales price (ASP) figures for nebulizer medications, but otherwise there were few major changes.